Daniel Pollyea, MD, MS, of the University of Colorado, Denver, CO, discusses the results of a study evaluating glasdegib, a hedgehog inhibitor, as maintenance therapy for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients at high-risk for post-allogeneic stem cell transplant relapse. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).